Guillain-Barré syndrome is a postinfectious, autoimmune neuropathy resulting in neuromuscular paralysis. Auto-antibodies, often induced by bacterial infection, bind to human gangliosides possessing monosialoside and diasialoside epitopes and impair the function of nerve junctions, where these ganglioside structures are highly enriched. Truncated gangliosides representive of GD3, GQ1b and GM2 epitopes have been synthesized as methyl glycosides and as a glycosides of an eleven carbon tether. The synthetic oligosaccharide ligands are structural mimics of these highly complex ganglioside epitopes and via their ability to neutralize or remove auto-antibodies have the potential for therapy, either as soluble blocking ligands administered systemically, or as immuno-affinity ligands for use as extracorporeal immunoadsorbents.
吉兰-巴雷综合征是一种感染后自身免疫性神经病,会导致神经肌肉麻痹。自身
抗体通常由细菌感染诱导,与具有单
神经节苷脂和二
神经节苷脂表位的人类
神经节苷脂结合,损害神经连接的功能,而这些
神经节苷脂结构在神经连接中高度富集。代表 GD3、GQ1b 和 GM2 表位的截短
神经节苷脂已被合成为
甲基糖苷和 11 个
碳系的糖苷。合成的
寡糖配体是这些高度复杂的
神经节苷脂表位的结构模拟物,通过其中和或清除自身
抗体的能力,具有治疗的潜力,既可以作为全身给药的可溶性阻断
配体,也可以作为体外免疫吸附剂使用的免疫亲和
配体。